Company Profile for Medicis

Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and podiatric conditions and aesthetics medicine. The Company is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis has leading branded prescription products in a number of therapeutic categories, including acne, eczema, fungal infections, psoriasis, rosacea, seborrheic dermatitis and skin and skin-structure infections. The Company's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance. The Company's products include the prescription brands RESTYLANE(R), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), OMNICEF(R) (cefdinir), PLEXION(R) (sodium sulfacetamide/sulfur), TRIAZ(R) (benzoyl peroxide), LIDEX(R) (fluocinonide), and SYNALAR(R) (fluocinolone acetonide), the over-the-counter brand ESOTERICA(R), and BUPHENYL(R) (sodium phenylbutyrate), a prescription product indicated in the treatment of Urea Cycle Disorder. For more information about Medicis, please visit the Company's website at www.medicis.com.

  Company:              Medicis

  Headquarters Address: 8125 North Hayden Road
                        Scottsdale, Arizona 85258-2463

  Main Telephone:       602-808-8800

  Website:              www.medicis.com

  Ticker:               MRX(NYSE)

  Type of Organization: Public

  Industry:             Health: Pharmaceutical

  Key Executives:       Chairman & Chief Executive Officer:
                        Jonah Shacknai

                        Executive Vice President &
                        Chief Financial Officer:
                        Mark A. Prygocki

  Investor Relations
  Contact:              Kara Stancell
  Phone:                602-808-3854
  Email:                investor_relations@medicis.com